Neuren announces changes to leadership team
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren commences first clinical trial for NNZ-2591
- Appendix 4C - quarterly
- Q1 2020 Activity Report
- First patent in Israel granted for trofinetide
- Temporary pause in new enrolments for LAVENDER trial in US
Later from Neuren Pharmaceuticals
- Temporary enrolment pause ended in Phase 3 trial in the US
- Neuren successfully completes $20m capital raising
- Proposed issue of Securities - NEU
- Q2 2020 Activity Report and Cash Flow Report
- Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals